Business
Alkermes develops and markets neuroscience medicines.
Alkermes contracted revenue, remained profitable, generated positive free cash flow at a 17.2% operating margin. Margins and free cash flow were strong, though the earnings-quality screen was grey and investment rose.
The read at a glance✓ Audited against SEC data
- Growth — Revenue declined 5.2%Watch
- Profitability — Net income declined 34.2% to $241.664M from $367.07MWatch
- Cash flow — Free cash flow grew 18.4% to $480.334M from $405.64MOK
- Margins — Operating margin contracted 979 bps to 17.21%Watch
- Accounting — Margins and free cash flow were strong, though the earnings-quality screen was grey and investment roseNote
- Insiders — 0 purchases and 23 salesWatch
Where the revenue comes from
Fiscal 2025, as Alkermes plc. reports it. History and quarterly detail are in the app.
- Product$1.2B
- Vivitrol$467.9M
- Aristada And Aristada Initio$370.0M
- LYBALVI$346.7M
- Manufactured Product And Royalty$291.3M
Leadership changes
From Alkermes plc.'s own filings, the day they're filed.
- Blair C. Jackson · Chief Operating Officer · departureeff. 2026-08-01
- Joshua Reed · Chief Financial Officer · appointmenteff. 2025-09-15
- Frank Anders Wilson · Director · appointmenteff. 2023-12-08
Latest filings
- 8-K · Company announcement2026-08-12
- 8-K · Company announcement2026-07-28
- 10-Q · Quarterly report2026-07-28
- 8-K · Company announcement2026-07-08
- 8-K · Company announcement2026-06-15
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Alkermes plc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.